Sign In
Buy AIM
$0.732
-0.0947 (-11.46%)
At Close: Jun 03, 2026
AIM ImmunoTech to file Investigational New Drug application for Ampligen to treat long COVID
09:01am, Wednesday, 18'th May 2022
AIM ImmunoTech Inc (NYSE:AIM) has announced that it is working towards filing an Investigational New Drug (IND) application with the US Food and Drug Administration (FDA) for its long COVID investigat
AIM ImmunoTech Reports First Quarter 2022 Financial Results and Provides Corporate Update
11:05am, Monday, 16'th May 2022 GlobeNewswire Inc.
- First quarter marked by peer-reviewed journal and abstract publications showcasing statistically significant efficacy data of Ampligen in late-stage pancreatic cancer; results also showcased continu
AIM ImmunoTech to Participate in a Solve M.E. Signature Event: ‘Long COVID: Research, Policy, and Economic Impact’ on May 19, 2022
12:05pm, Thursday, 12'th May 2022 GlobeNewswire Inc.
OCALA, Fla., May 12, 2022 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE: American AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeut
AIM ImmunoTech Provides Summary of Ampligen® Data Supporting Synergistic Potential with Checkpoint Blockade Therapies
12:05pm, Thursday, 21'st Apr 2022 GlobeNewswire Inc.
Ampligen has demonstrated in pre-clinical and now human clinical studies a potential to enhance efficacy of PD-1 and/or PD-L1 checkpoint inhibitors
AIM ImmunoTech says Ampligen data supports synergistic potential with checkpoint blockade therapies
10:11am, Thursday, 21'st Apr 2022
AIM ImmunoTech Inc (NYSE:AIM) has provided a summary of positive clinical data supporting the synergistic potential of its flagship drug Ampligen (rintatolimod) with checkpoint blockade therapies. I
AIM ImmunoTech Provides Progress on Advancement of Ampligen® Clinical Development Program for the Treatment of Pancreatic Cancer
11:47am, Tuesday, 12'th Apr 2022 GlobeNewswire Inc.
- Ampligen® (rintatolimod) has demonstrated promising activity as a potential maintenance therapy after systemic chemotherapy in patients with advanced pancreatic cancer
AIM ImmunoTech engages CRO Amarex Clinical Research to manage Phase 2 of Ampligen study
09:01am, Tuesday, 12'th Apr 2022
AIM ImmunoTech Inc (NYSE:AIM). has engaged Amarex Clinical Research LLC to manage the Phase 2 study of its flagship drug candidate Ampligen as a therapy for locally advanced pancreatic cancer (AMP-270
Best Penny Stocks Right Now? 3 to Watch as HOTH Stock Explodes
01:36pm, Monday, 11'th Apr 2022 PennyStocks
What you need to know about trading penny stocks on April 11th
The post Best Penny Stocks Right Now? 3 to Watch as HOTH Stock Explodes appeared first on Penny Stocks to Buy, Picks, News and Informat
AIM ImmunoTech Inc (NYSE:AIM) presented positive data from its ongoing Phase 2a clinical study at the Roswell Park Comprehensive Cancer Center evaluating its flagship drug Ampligen (rintatolimod) as
AIM ImmunoTech Announces Positive Data from Phase 2a Study Evaluating Ampligen® as a Component of a Chemokine Modulatory (CKM) Regimen for the Treatment of Colorectal Cancer Metastatic to the Liver
11:05am, Monday, 11'th Apr 2022 GlobeNewswire Inc.
Primary endpoint of the study was met, evidenced by increased CD8a expression post-treatment (p=0.046)
AIM ImmunoTech Announces Positive Data from Phase 1 Study Evaluating Ampligen® for the Treatment of Stage 4 Metastatic Triple Negative Breast Cancer
11:05am, Monday, 11'th Apr 2022 GlobeNewswire Inc.
Phase 1 study of metastatic triple-negative breast cancer using chemokine modulation (CKM) therapy, including Ampligen and pembrolizumab, successfully met primary endpoint
Best Penny Stocks Right Now? 3 to Watch as HOTH Stock Explodes
09:36am, Monday, 11'th Apr 2022
What you need to know about trading penny stocks on April 11th The post Best Penny Stocks Right Now? 3 to Watch as HOTH Stock Explodes appeared first on Penny Stocks to Buy, Picks, News and Informat
AIM ImmunoTech Shares Jump On Positive Data From Ampligen Study In Breast Cancer Setting
09:30am, Monday, 11'th Apr 2022
AIM ImmunoTech Inc (NYSE: AIM) has announced the presentation of positive data from a Phase 1 study of Ampligen in metastatic triple-negative breast cancer. The pre-determined primary efficacy endp
AIM ImmunoTech报告2021年第四季度和全年财务业绩并通报企业最新情况
02:31am, Saturday, 02'nd Apr 2022 GlobeNewswire Inc.
- 该年度继续执行临床开发项目并不断累积越来越多的在多个高价值的适应症中使用Ampligen®的积极数据
AIM ImmunoTech reports ‘strong' balance sheet to fund operations and clinical development programs through 2023
08:54am, Friday, 01'st Apr 2022
AIM ImmunoTech Inc (NYSE:AIM) said it has a “strong” balance sheet that will fund operations and clinical development programs through 2023. In a statement reporting its financial results for 20
